# Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

> **NCT04150497** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cellectis S.A.** · enrollment: 52 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** UCART22
- **BIOLOGICAL:** CLLS52

## Key facts

- **NCT ID:** NCT04150497
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-14
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150497, "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04150497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*